TheraBionic P1
Advanced Hepatocellular Carcinoma (HCC)
Approved/CommercialActive
Key Facts
Indication
Advanced Hepatocellular Carcinoma (HCC)
Phase
Approved/Commercial
Status
Active
Company
About TheraBionic
TheraBionic is a private, commercial-stage oncology company focused on a novel, non-invasive treatment modality using tumor-specific radiofrequency electromagnetic fields. Its lead product, the TheraBionic P1, is indicated for patients with advanced hepatocellular carcinoma who have failed or are intolerant to first and second-line therapies, positioning it as a late-line treatment option. The technology, co-invented by founders Boris Pasche and Alexandre Barbault, aims to block tumor growth without significant side effects. The company appears to be in an early commercial or limited-access phase, with the device available by prescription.
View full company profileTherapeutic Areas
Other Advanced Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ECT204 | Eureka Therapeutics | Phase 1/2 |